Research map: Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Back to the article

Papers in this map

  1. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis · David T. Felson · 1995 · 2850 citations · Cited by this paper
  2. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial · Désirée M F M van der Heijde · 2026 · 1 citation · Cites this paper
  3. The Role of IgM Anti‐acetylated Protein Antibodies and B Cells in the Origin of Antimodified Protein Autoimmunity in Rheumatoid Arthritis · 2026 · Related
  4. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis · Steven R. Ytterberg · 2022 · 1819 citations · Cited by this paper
  5. TYK2 inhibition shows durable efficacy in PsA · Jessica McHugh · 2026 · Cites this paper
  6. Reply · 2026 · Related
  7. Psoriatic Arthritis · Christopher T. Ritchlin · 2017 · 1422 citations · Cited by this paper
  8. Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis · 2026 · Related
  9. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 · Laura C. Coates · 2022 · 626 citations · Cited by this paper
  10. Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression · 2026 · Related
  11. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis · Kim Alexander Papp · 2018 · 425 citations · Cited by this paper
  12. Dermatomyositis in skin of color population: expanding clinical recognition · 2026 · Related
  13. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 · Stephen T. Wrobleski · 2019 · 389 citations · Cited by this paper
  14. Age‐associated B cells contribute to inflammation via antibody‐independent mechanisms in Takayasu's arteritis · 2026 · Related
  15. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update · Laure Gossec · 2024 · 377 citations · Cited by this paper
  16. Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD ‐ PRO Registry · 2026 · Related
  17. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? · Kenneth Frank Baker · 2017 · 373 citations · Cited by this paper
  18. Cytokine‐induced NRP2 expression in rheumatoid arthritis fibroblast‐like synoviocytes: comment on the article by Jin et al · 2026 · Related
  19. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial · April Wang Armstrong · 2022 · 373 citations · Cited by this paper
  20. Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart · 2026 · Related
  21. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial · Bruce E Strober · 2022 · 300 citations · Cited by this paper
  22. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial · Eric Francis Morand · 2022 · 268 citations · Cited by this paper
  23. The regulation of JAKs in cytokine signaling and its breakdown in disease · Henrik M. Hammarén · 2018 · 224 citations · Cited by this paper
  24. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance · Christina Charles‐Schoeman · 2022 · 219 citations · Cited by this paper
  25. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis · Philip J. Mease · 2022 · 217 citations · Cited by this paper
  26. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases · Lluís Rusiñol · 2023 · 81 citations · Cited by this paper
  27. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors · Lise Torp Jensen · 2023 · 79 citations · Cited by this paper
  28. Pathogenesis of psoriatic arthritis · Carmel B. Stober · 2021 · 54 citations · Cited by this paper
  29. Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis · Mariele Zardin-Moraes · 2019 · 41 citations · Cited by this paper
  30. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials · April Wang Armstrong · 2025 · 41 citations · Cited by this paper
  31. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study · Maya H Buch · 2024 · 21 citations · Cited by this paper
  32. Unmet needs in psoriatic arthritis, a narrative review · Clementina López‐Medina · 2024 · 13 citations · Cited by this paper
  33. Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis · Gian Luca Erre · 2021 · 11 citations · Cited by this paper
  34. Clinical enthesitis in patient with psoriatic arthritis, a systematic literature review with metaanalysis · Caroline Pignon · 2024 · 10 citations · Cited by this paper
  35. Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada · F. Nantel · 2022 · 6 citations · Cited by this paper
  36. Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials · April Wang Armstrong · 2025 · 4 citations · Cited by this paper
  37. Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disorders · Arvind Shakya · 2025 · 2 citations · Cited by this paper
  38. Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database · Andreas Pinter · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)